Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
We are committed to the relentless pursuit of science that can improve the lives of patients.
Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity.
Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia.
We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list.
For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.
Oncology, Immuno-oncology, Targeted Therapy, Immunology, and Inflammation
Biopharmaceutical Company | Solutions for Unmet Medical Needs | Incyte.com
Entity | Type | Tweets | Articles | |
---|---|---|---|---|
USPO healthtech, Public Policy Offices | Other 14 Oct 2024 | | ||
First Ascent it services, martech, Design Services | Other 26 Oct 2024 | | ||
iSanidad Online Audio and Video Media | Other 31 Oct 2024 | | ||
H1 healthtech, Software Development | Other 12 Sep 2024 | | ||
SNDV - Syndicat National des Dermatologues-Vénéréologues entertainment | Other 31 May 2024 | | ||
Les Echos Etudes constructiontech, agritech, Market Research, healthtech, martech, transporttech | Other 28 Jun 2024 | | ||
BioInnova Consulting consulting, healthtech, Business Consulting and Services | Other 22 Jun 2024 | | ||
5AM Ventures Venture Capital and Private Equity Principals | Other 30 Apr 2024 | | ||
pharma.be deeptech, healthtech, Pharmaceutical Manufacturing | Other 24 May 2024 | | ||
Abingworth Venture Capital and Private Equity Principals | Other 30 Apr 2024 | |